CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 230 enrolled
Drug / intervention
Calcifedioldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06279910
NCT06279910N/ACompleted
CompareCT.gov

Inclusion of Calcifediol in the Hospital Therapeutic Protocol for Treatment of SARS-CoV-2 Disease (COVID-19). Mortality Analysis. Retrospective Study.

Complejo Hospitalario Universitario de Albacete·observational·Posted Feb 28, 2024·Updated Jun 5, 2025

In Brief

An observational study evaluating Calcifediol for SARS-CoV 2 Pneumonia. Completed, enrolled 230 participants across 1 site.

Detailed Summary

Descriptive, retrospective, observational, anonymous, study to evaluate the potential effect of incorporating calcifediol into the therapeutic protocol of patients hospitalized for COVID-19 on mortality and other outcome variables, such as admission to the Intensive Care Unit (ICU), to "Complejo Hospitalario Universitario de Albacete" (CHUA). Albacete (Spain)", based on the files of the MXXI medical records, Information System of the Laboratory (ISL) and Pharmacy.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV 2 Pneumonia
CountriesSpain
Collaborators--

Timeline

N/ACompletedFinished
20252026
First PostedFeb 28, 2024
Enrollment StartFeb 21, 2024
Primary CompletionMar 21, 2024
Study CompletionApr 25, 2024
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 2.3 years ago

Interventions

Calcifedioldrug

Calcifediol added as a treatment to the rest of the prescribed drugs of the protocol